Fluid biomarker and electrophysiological outcome measures for progressive MS trials

Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis

(2017) I. Håkansson et al.   EUROPEAN JOURNAL OF NEUROLOGY

Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial

(2017) Diego Cadavid et al.   LANCET NEUROLOGY

A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS

(2017) Martin Hardmeier et al.   Multiple Sclerosis Journal

Brain-derived neurotrophic factor levels under chronic natalizumab treatment in multiple sclerosis. A preliminary report

(2017) Vitalie Văcăraş et al.   Neurologia i Neurochirurgia Polska

Serum neurofilament is associated with progression of brain atrophy and disability in early MS

(2017) Jens Kuhle et al.   NEUROLOGY

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

(2017) Niklas Mattsson et al.   JAMA Neurology

A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS

(2017) Martin Hardmeier et al.   Multiple Sclerosis Journal

Multimodal evoked potentials for functional quantification and prognosis in multiple sclerosis

(2016) Xavier Giffroy et al.   BMC Neurology

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa

(2016) Jens Kuhle et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis

(2016) J. Mellergård et al.   EUROPEAN JOURNAL OF NEUROLOGY

Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis

(2016) Lenka Novakova et al.   JOURNAL OF NEUROCHEMISTRY

YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis

(2016) Joachim Burman et al.   JOURNAL OF NEUROIMMUNOLOGY

Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis

(2016) M.Alba Mañé-Martínez et al.   JOURNAL OF NEUROIMMUNOLOGY

Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum

(2016) Carlo Wilke et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis

(2016) Lenka Novakova et al.   Multiple Sclerosis Journal

Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity

(2016) Jens Kuhle et al.   Multiple Sclerosis Journal

Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab

(2016) Pierre de Flon et al.   NEUROLOGY

Neurofilament light chain level is a weak risk factor for the development of MS

(2016) Georgina Arrambide et al.   NEUROLOGY

Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases

(2016) Mehtap Bacioglu et al.   NEURON

Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis

(2016) Lenka Novakova et al.   Multiple Sclerosis Journal

Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity

(2016) Jens Kuhle et al.   Multiple Sclerosis Journal

Cognitive event-related potentials in multiple sclerosis: Correlation with MRI and neuropsychological findings

(2016) Vasilios K. Kimiskidis et al.   Multiple Sclerosis and Related Disorders

Plasma neurofilament light chain predicts progression in progressive supranuclear palsy

(2016) Julio C. Rojas et al.   Annals of Clinical and Translational Neurology

Neurofilament light chain: a biomarker for genetic frontotemporal dementia

(2016) Lieke H. Meeter et al.   Annals of Clinical and Translational Neurology

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study

(2016) Magnus Gisslén et al.   EBioMedicine

Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis

(2015) Patrick Weydt et al.   ANNALS OF NEUROLOGY

Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes

(2015) Ester Cantó et al.   BRAIN

Evoked potentials and disability in multiple sclerosis: A different perspective to a neglected method

(2015) Nefati Kiylioglu et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Event related potential and response time give evidence for a physiological reserve in cognitive functioning in relapsing–remitting multiple sclerosis

(2015) Mathias Sundgren et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis

(2015) M Alba Mañé Martínez et al.   Multiple Sclerosis Journal

Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis

(2015) G Hinsinger et al.   Multiple Sclerosis Journal

Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis

(2015) C.-H. Lu et al.   NEUROLOGY

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis

(2015) J. Kuhle et al.   NEUROLOGY

Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis

(2015) M Alba Mañé Martínez et al.   Multiple Sclerosis Journal

Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis

(2015) G Hinsinger et al.   Multiple Sclerosis Journal

Multimodal neurophysiological evaluation of primary progressive multiple sclerosis – An increasingly valid biomarker, with limits

(2015) L.J.W. Canham et al.   Multiple Sclerosis and Related Disorders

Assessing tissue damage in multiple sclerosis: a biomarker approach

(2014) J. Burman et al.   ACTA NEUROLOGICA SCANDINAVICA

Reproducibility of multifocal visual evoked potential and traditional visual evoked potential in normal and multiple sclerosis eyes

(2014) Divya Narayanan et al.   DOCUMENTA OPHTHALMOLOGICA

Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis

(2014) L. M. Villar et al.   EUROPEAN JOURNAL OF NEUROLOGY

N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis

(2014) Alessandro Trentini et al.   JOURNAL OF NEUROLOGY

Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients

(2014) M. M. Gresle et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

No evidence for an association of osteopontin plasma levels with disease activity in multiple sclerosis

(2014) Tessel F Runia et al.   Multiple Sclerosis Journal

Optical coherence tomography and visual evoked potentials: which is more sensitive in multiple sclerosis?

(2014) Giovanni Di Maggio et al.   Multiple Sclerosis Journal

Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial

(2014) J. Romme Christensen et al.   NEUROLOGY

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis

(2013) J. Kuhle et al.   ACTA NEUROLOGICA SCANDINAVICA

Central motor conduction time may predict response to fampridine in patients with multiple sclerosis

(2013) D. Zeller et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis–osteopontin as a potential marker of clinical severity

(2013) Levente Szalardy et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Body fluid biomarkers in multiple sclerosis

(2013) Manuel Comabella et al.   LANCET NEUROLOGY

Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis

(2013) Regina Schlaeger et al.   Multiple Sclerosis Journal

Evoked potentials are of little use in the diagnosis or monitoring of MS: No

(2013) Oscar Fernández et al.   Multiple Sclerosis Journal

CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions

(2013) Enrique Alvarez et al.   Multiple Sclerosis Journal

Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development

(2013) Pia Kivisäkk et al.   Multiple Sclerosis Journal

Cortical plasticity predicts recovery from relapse in multiple sclerosis

(2013) Francesco Mori et al.   Multiple Sclerosis Journal

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis

(2013) Markus Axelsson et al.   Multiple Sclerosis Journal

A comparative study of CSF neurofilament light and heavy chain protein in MS

(2013) Jens Kuhle et al.   Multiple Sclerosis Journal

Retest Reliability of Individual P3 Topography Assessed by High Density Electroencephalography

(2013) Manuel Vázquez-Marrufo et al.   PLoS One

Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression

(2013) Sharmilee Gnanapavan et al.   PLoS One

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

(2013) Johanna Gaiottino et al.   PLoS One

Relationship between Cerebrospinal Fluid Biomarkers for Inflammation, Demyelination and Neurodegeneration in Acute Optic Neuritis

(2013) Signe Modvig et al.   PLoS One

Serum GFAP levels in optic neuropathies

(2012) Mithu Storoni et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

(2012) Peter Connick et al.   LANCET NEUROLOGY

CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis

(2012) Jeppe Romme Christensen et al.   Multiple Sclerosis Journal

CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome

(2012) M Khalil et al.   Multiple Sclerosis Journal

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid

(2011) Samia Ragheb et al.   Multiple Sclerosis Journal

Simvastatin improves final visual outcome in acute optic neuritis: a randomized study

(2011) Anna Tsakiri et al.   Multiple Sclerosis Journal

The Use of Serum Glial Fibrillary Acidic Protein Measurements in the Diagnosis of Neuromyelitis Optica Spectrum Optic Neuritis

(2011) Mithu Storoni et al.   PLoS One

Evidence for acute neurotoxicity after chemotherapy

(2010) Axel Petzold et al.   ANNALS OF NEUROLOGY

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis

(2010) Manuel Comabella et al.   BRAIN

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis

(2010) M. Axelsson et al.   JOURNAL OF NEUROLOGY

Neurofilament light as a prognostic marker in multiple sclerosis

(2010) Jonatan Salzer et al.   Multiple Sclerosis Journal

Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis

(2010) Lars Börnsen et al.   Multiple Sclerosis Journal

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course

(2010) Mohsen Khademi et al.   Multiple Sclerosis Journal

Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations

(2010) David M Rissin et al.   NATURE BIOTECHNOLOGY

Astrocytic damage is far more severe than demyelination in NMO: A clinical CSF biomarker study

(2010) R. Takano et al.   NEUROLOGY

The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS)

(2010) Johannes Brettschneider et al.   PLoS One

The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers

(2009) M. Khademi et al.   EUROPEAN JOURNAL OF NEUROLOGY

Serum levels of CXCL13 are elevated in active multiple sclerosis

(2009) Eugene D Festa et al.   Multiple Sclerosis Journal

Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS

(2009) F. Sellebjerg et al.   NEUROLOGY

Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis

(2009) C. E. Teunissen et al.   NEUROLOGY

Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse

(2009) Elizabeth Regina Comini Frota et al.   NEUROSCIENCE LETTERS

Multifocal VEP and OCT in optic neuritis: a topographical study of the structure–function relationship

(2008) Alexander Klistorner et al.   DOCUMENTA OPHTHALMOLOGICA

A comparison of multifocal and conventional visual evoked potential techniques in patients with optic neuritis/multiple sclerosis

(2008) Larissa K. Grover et al.   DOCUMENTA OPHTHALMOLOGICA

Phosphorylation and compactness of neurofilaments in multiple sclerosis: Indicators of axonal pathology

(2008) Axel Petzold et al.   EXPERIMENTAL NEUROLOGY

The Phosphorylated Axonal Form of the Neurofilament Subunit NF-H (pNF-H) as a Blood Biomarker of Traumatic Brain Injury

(2008) Kevin J. Anderson et al.   JOURNAL OF NEUROTRAUMA

Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event

(2008) J.-C. Corvol et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA